Breast cancer patients, take note: a groundbreaking test is here to revolutionize your treatment journey! PreludeDx introduces AidaBreast™, the first of its kind to predict locoregional recurrence risk and radiation therapy benefits for early-stage invasive breast cancer. But here's where it gets controversial—is this test the holy grail for personalized treatment, or are there limitations to its impact?
In a recent study presented at the San Antonio Breast Cancer Symposium (SABCS) 2025, Dr. Bruce Mann and Troy Bremer, PhD, unveiled the independent validation of AidaBreast. This test is a game-changer for women with early-stage HR+ / HER2- invasive breast cancer who have undergone breast-conserving surgery and endocrine therapy. The validation study, conducted at Royal Melbourne Hospital, Australia, revealed:
- AidaBreast's ability to categorize women into Low Risk and Elevated Risk groups based on tumor biology.
- Within the Elevated Risk group, it identifies those who will benefit significantly from radiation therapy (RT) and those who won't, despite the elevated recurrence risk.
- Women in the Low Risk group had remarkably low 10-year recurrence rates, regardless of radiation therapy.
Dr. Mann emphasized, "AidaBreast offers a major breakthrough by providing information beyond clinicopathology, helping patients and doctors make informed choices." But here's the part most people miss—how does this test impact treatment decisions?
AidaBreast utilizes multi-omic technology, analyzing RNA, protein expression, and spatial biology to understand a patient's tumor biology comprehensively. This level of detail is unprecedented, allowing patients and physicians to make shared treatment decisions with confidence, especially regarding radiation therapy.
As the first commercially available test for RT in Stage I and IIa breast cancer, AidaBreast fills a critical gap. Unlike previous tests focused on metastatic risk, it assesses both recurrence risk and RT benefit. This innovation is built on PreludeDx's success with DCISionRT®, a widely adopted test for ductal carcinoma in situ (DCIS) patients.
DCISionRT has been a game-changer, enabling doctors to understand DCIS biology better. It provides a Decision Score that categorizes a woman's risk as low, elevated, or residual, helping personalize treatment decisions. PreludeDx aims to extend this impact to early-invasive breast cancer with AidaBreast.
In summary, AidaBreast is a significant advancement in early-stage breast cancer treatment, offering a more precise and personalized approach. But the question remains: how widely accessible and effective will this test be in clinical practice? Share your thoughts in the comments below!
